Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8WVX9

UPID:
FACR1_HUMAN

ALTERNATIVE NAMES:
Male sterility domain-containing protein 2

ALTERNATIVE UPACC:
Q8WVX9; D3DQW8; Q5CZA3

BACKGROUND:
The enzyme Fatty acyl-CoA reductase 1, alternatively known as Male sterility domain-containing protein 2, is integral to the synthesis of fatty alcohols from fatty acyl-CoA substrates. These fatty alcohols serve as precursors for ether lipids/plasmalogens and wax monoesters, playing a critical role in cell membrane structure and function.

THERAPEUTIC SIGNIFICANCE:
Given its association with severe metabolic disorders such as Peroxisomal fatty acyl-CoA reductase 1 disorder and conditions featuring cataracts and spastic paraparesis, Fatty acyl-CoA reductase 1 emerges as a promising target for drug discovery. Exploring its function could lead to breakthroughs in treating these debilitating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.